Document Detail

Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
MedLine Citation:
PMID:  23143665     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: Anti-TNF-alpha therapy with monoclonal antibodies (adalimumab and infliximab) did not only suppress disease activity but also provided a significant improvement in HGB levels. In the groups of treated with a TNF-alpha receptor antagonist (ETA) and non-biological agents, disease activity was suppressed, but there was not founded significant improvement in HGB levels after 52 weeks. Different outcomes of anti-TNF agents may be associated with their different effect mechanisms.
Cemal Bes; Ayten Yazici; Mehmet Soy
Related Documents :
23363895 - Relation of inflammatory and oxidative markers to the occurrence and recurrence of pers...
23624135 - Salivary cortisol day curves in assessing glucocorticoid replacement therapy in addison...
25011935 - Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic ...
23695065 - Diagnostic delay in migraine with aura.
19827955 - Association of mannose-binding lectin deficiency with acute invasive aspergillosis in i...
21541835 - Feasibility of tee-guided stroke risk assessment in atrial fibrillation-background, aim...
Publication Detail:
Type:  Journal Article     Date:  2012-11-13
Journal Detail:
Title:  Rheumatology international     Volume:  33     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-27     Completed Date:  2014-01-13     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1415-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents / therapeutic use*
Blood Sedimentation
C-Reactive Protein / analysis
Hemoglobins / analysis*
Immunoglobulin G / therapeutic use
Middle Aged
Receptors, Tumor Necrosis Factor / therapeutic use
Spondylitis, Ankylosing / blood,  drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Hemoglobins; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; 9007-41-4/C-Reactive Protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stylopsal: The First Identified Female-produced Sex Pheromone of Strepsiptera.
Next Document:  Survivin in Adrenocortical Tumors - Pathophysiological Implications and Therapeutic Potential.